WO2003068169A3 - Stabilized synthetic immunogen delivery system - Google Patents

Stabilized synthetic immunogen delivery system Download PDF

Info

Publication number
WO2003068169A3
WO2003068169A3 PCT/US2003/004711 US0304711W WO03068169A3 WO 2003068169 A3 WO2003068169 A3 WO 2003068169A3 US 0304711 W US0304711 W US 0304711W WO 03068169 A3 WO03068169 A3 WO 03068169A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunostimulatory complex
suspension
immune response
delivery system
immunogen
Prior art date
Application number
PCT/US2003/004711
Other languages
French (fr)
Other versions
WO2003068169A2 (en
Inventor
Kenneth K Sokoll
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2475102A priority Critical patent/CA2475102C/en
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Priority to EP03709134A priority patent/EP1572074B1/en
Priority to AT03709134T priority patent/ATE540697T1/en
Priority to CN03804021.2A priority patent/CN101001646B/en
Priority to ES03709134T priority patent/ES2383172T3/en
Priority to AU2003213091A priority patent/AU2003213091C1/en
Priority to DK03709134.5T priority patent/DK1572074T3/en
Priority to BRPI0307724A priority patent/BRPI0307724B8/en
Priority to MXPA04007935A priority patent/MXPA04007935A/en
Priority to JP2003567354A priority patent/JP5156170B2/en
Publication of WO2003068169A2 publication Critical patent/WO2003068169A2/en
Priority to HK06103311.0A priority patent/HK1085652A1/en
Publication of WO2003068169A3 publication Critical patent/WO2003068169A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Abstract

The present invention provides an immunostimulatory complex specifically adapted to act as adjuvant and as a peptide immunogen stabilizer. The immunostimulatory complex comprises a CpG oligonucleotide and a biologically active peptide immunogen. The immunostimulatory complex is particulate and can efficiently present peptide immunogens to the cells of the immune system to produce an immune response. The immunostimulatory complex may be formulated as a suspension for parenteral administration. The immunostimulatory complex may also be formulated in the form of w/o-emulsions, as a suspension in combination with a mineral salt suspension or with an in-situ gelling polymer for the efficient delivery of an immunogen to the cells of the immune system of a subject following parenteral administration, to produce an immune response which may also be a protective immune response.
PCT/US2003/004711 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery system WO2003068169A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2003213091A AU2003213091C1 (en) 2002-02-14 2003-02-14 Stabilized Synthetic Immunogen Delivery System
EP03709134A EP1572074B1 (en) 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery system
AT03709134T ATE540697T1 (en) 2002-02-14 2003-02-14 STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM
CN03804021.2A CN101001646B (en) 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery system
ES03709134T ES2383172T3 (en) 2002-02-14 2003-02-14 Synthetic stabilized immunogen delivery system
CA2475102A CA2475102C (en) 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery systems
DK03709134.5T DK1572074T3 (en) 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery system
JP2003567354A JP5156170B2 (en) 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery system
MXPA04007935A MXPA04007935A (en) 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery system.
BRPI0307724A BRPI0307724B8 (en) 2002-02-14 2003-02-14 systems for delivering stabilized synthetic immunogens
HK06103311.0A HK1085652A1 (en) 2002-02-14 2006-03-14 Stabilized synthetic immunogen delivery system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/076,674 2002-02-14
US10/076,674 US8088388B2 (en) 2002-02-14 2002-02-14 Stabilized synthetic immunogen delivery system
US10/355,161 2003-01-31
US10/355,161 US8084015B2 (en) 2002-02-14 2003-05-21 Stabilized synthetic immunogen delivery system

Publications (2)

Publication Number Publication Date
WO2003068169A2 WO2003068169A2 (en) 2003-08-21
WO2003068169A3 true WO2003068169A3 (en) 2007-03-15

Family

ID=33422414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004711 WO2003068169A2 (en) 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery system

Country Status (14)

Country Link
US (2) US8088388B2 (en)
EP (1) EP1572074B1 (en)
JP (2) JP5156170B2 (en)
CN (2) CN101001646A (en)
AT (1) ATE540697T1 (en)
AU (1) AU2003213091C1 (en)
BR (1) BRPI0307724B8 (en)
CA (1) CA2475102C (en)
DK (1) DK1572074T3 (en)
ES (1) ES2383172T3 (en)
HK (1) HK1085652A1 (en)
MX (1) MXPA04007935A (en)
TW (1) TWI359025B (en)
WO (1) WO2003068169A2 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US20090030309A1 (en) 2007-07-26 2009-01-29 Senorx, Inc. Deployment of polysaccharide markers
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
EP1919388B1 (en) 2000-11-20 2012-12-26 Senorx, Inc. Tissue site markers for in vivo imaging
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
WO2004014322A2 (en) * 2002-08-12 2004-02-19 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US7877133B2 (en) * 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
CN100379408C (en) * 2003-07-28 2008-04-09 马林克罗特公司 Improved stearate composition and preparation method
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
CA2562580C (en) 2005-10-07 2014-04-29 Inrad, Inc. Drug-eluting tissue marker
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US8064987B2 (en) 2006-10-23 2011-11-22 C. R. Bard, Inc. Breast marker
US9579077B2 (en) 2006-12-12 2017-02-28 C.R. Bard, Inc. Multiple imaging mode tissue marker
ES2432572T3 (en) 2006-12-18 2013-12-04 C.R. Bard, Inc. Biopsy marker with imaging properties generated in situ
JP2008174490A (en) * 2007-01-18 2008-07-31 Nitto Denko Corp Medicinal agent containing antigenic peptide as main component
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology Poly (amino acid) targeting moieties
JP2008308474A (en) * 2007-06-18 2008-12-25 Nitto Denko Corp Method for preparing antigenic peptide preparation
ES2627233T3 (en) 2007-10-12 2017-07-27 Massachusetts Institute Of Technology Vaccine Nanotechnology
WO2009099767A2 (en) 2008-01-31 2009-08-13 C.R. Bard, Inc. Biopsy tissue marker
DE102008024470B4 (en) * 2008-05-21 2022-10-20 Faurecia Emissions Control Technologies, Germany Gmbh Method for regenerating an exhaust gas cleaning filter and evaporator
CN104001170B (en) 2008-06-27 2016-08-24 硕腾有限责任公司 Novel adjunvant composition
US20090005320A1 (en) * 2008-09-02 2009-01-01 Bruce Kneller Compositions comprising amino acid bicarbonate and methods of use thereof
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
ES2622562T3 (en) 2008-12-09 2017-07-06 Pfizer Vaccines Llc IgE CH3 peptide vaccine
WO2010077244A1 (en) 2008-12-30 2010-07-08 C.R. Bard Inc. Marker delivery device for tissue marker placement
AU2010254551B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
CN105175516B (en) * 2009-06-04 2018-11-27 中牧实业股份有限公司 A kind of peptide vaccine for animal and its preparation
CN103002919B (en) * 2010-02-04 2015-03-25 得克萨斯系统大学评议会 Tumor targeted delivery of immunomodulators by nanoplymers
JP5835741B2 (en) * 2010-02-26 2015-12-24 国立大学法人 長崎大学 Antigen or drug delivery complex
NO2575876T3 (en) 2010-05-26 2018-05-05
MX352641B (en) * 2010-07-08 2017-12-01 United Biomedical Inc Designer peptide-based pcv2 vaccine.
US20120070459A1 (en) * 2010-09-22 2012-03-22 Goovaerts Daniel G E Method for keeping a foot-and-mouth disease vaccine available for emergency vaccination
CN102010461B (en) * 2010-10-11 2014-02-12 华南理工大学 Alpha spiral cation polypeptide molecule and preparation method and application thereof
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc Modified nicotinic compounds and related methods
JP5930146B2 (en) * 2011-03-28 2016-06-08 国立研究開発法人物質・材料研究機構 Immunostimulatory oligonucleotide and therapeutic agent comprising said immunostimulatory oligonucleotide
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
US10300123B2 (en) 2011-12-30 2019-05-28 United Biomedical, Inc. Synthetic peptide-based marker vaccine and diagnostic system for effective control of porcine reproductive and respiratory syndrome (PRRS)
BR112015010756B1 (en) 2012-11-16 2022-04-12 United Biomedical, Inc Vaccine compositions for foot-and-mouth disease (FMD), and use thereof
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
JP6697384B2 (en) 2013-07-25 2020-05-20 イグジキュア, インコーポレーテッドExicure, Inc. Spherical nucleic acid-based constructs as immunostimulants for prophylactic and therapeutic use
NZ733383A (en) * 2013-09-19 2022-12-23 Zoetis Services Llc Oil-based adjuvants
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
CN105906693B (en) * 2014-03-07 2020-01-14 中牧实业股份有限公司 Synthetic peptide vaccine and preparation method and application thereof
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
UA125607C2 (en) * 2014-07-25 2022-05-04 Юнайтед Байомедикал, Інк. Veterinary composition for pig immunocastration
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US9502964B2 (en) * 2014-12-16 2016-11-22 Intel Corporation Systems and methods for skewing DC/DC converter phases to mitigate spurs
JP7113620B2 (en) * 2015-01-16 2022-08-05 ゾエティス・サービシーズ・エルエルシー foot and mouth disease vaccine
EP3256850A4 (en) * 2015-02-09 2018-10-10 Slingshot Biosciences, Inc. Hydrogel particles with tunable optical properties and methods for using the same
LT3325015T (en) * 2015-07-20 2021-08-10 Zoetis Services Llc Liposomal adjuvant compositions
WO2017043490A1 (en) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 Double-stranded ribonucleic acid having enhanced natural immunity inducing effect
EP3463446A1 (en) 2016-06-02 2019-04-10 Zoetis Services LLC Vaccine against infectious bronchitis
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
CN107703294B (en) * 2017-10-12 2019-06-04 华派生物工程集团有限公司 It is a kind of for detecting the ELISA method of cLHRH antibody titer in chicken serum

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025060A1 (en) * 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5135751A (en) * 1988-11-16 1992-08-04 Mediventures Incorporated Composition for reducing postsurgical adhesions
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
GB8921470D0 (en) 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
DK0454044T3 (en) * 1990-04-25 1996-04-22 Hoechst Ag Pharmacological preparation containing polyelectrolyte complexes in microparticle form and at least one active substance
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
AU659482B2 (en) 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2560114A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6042820A (en) * 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1009386B1 (en) * 1997-08-29 2005-08-31 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
ATE233097T1 (en) * 1997-11-07 2003-03-15 Chiron Corp METHOD FOR PRODUCING SUSTAINED RELEASE IGF-I FORMULATIONS
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
EP1087784A1 (en) 1998-06-20 2001-04-04 United Biomedical, Inc. Synthetic somatostatin immunogen for growth promotion in farm animals
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
CA2689696C (en) * 1999-02-26 2013-08-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
AT409085B (en) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh PHARMACEUTICAL COMPOSITION FOR IMMUNULATING AND PRODUCING VACCINES
RU2293573C2 (en) * 2000-06-08 2007-02-20 Интерселл Аг Immunostimulating oligodeoxynucleotides
AT410173B (en) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh ANTIQUE COMPOSITION
JP2003535907A (en) * 2000-06-22 2003-12-02 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Method for promoting antibody-induced cell lysis and treating cancer
US20030055014A1 (en) * 2000-12-14 2003-03-20 Bratzler Robert L. Inhibition of angiogenesis by nucleic acids
US6780969B2 (en) * 2000-12-22 2004-08-24 United Biomedical, Inc. Synthetic peptide composition as immunogens for prevention of urinary tract infection
JP2004529906A (en) * 2001-03-19 2004-09-30 イオマイ コーポレイシヨン Percutaneous immunostimulation
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
AR040996A1 (en) * 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
BRPI0412855B8 (en) * 2003-07-24 2022-06-28 Merial Inc vaccine formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025060A1 (en) * 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids

Also Published As

Publication number Publication date
AU2003213091A1 (en) 2003-09-04
US8084015B2 (en) 2011-12-27
CA2475102A1 (en) 2003-08-21
TW200307557A (en) 2003-12-16
AU2003213091B2 (en) 2008-06-05
CA2475102C (en) 2013-04-23
CN101001646B (en) 2014-01-01
EP1572074B1 (en) 2012-01-11
CN101001646A (en) 2007-07-18
TWI359025B (en) 2012-03-01
US20030165478A1 (en) 2003-09-04
EP1572074A2 (en) 2005-09-14
HK1085652A1 (en) 2006-09-01
JP2010265291A (en) 2010-11-25
JP2005530690A (en) 2005-10-13
US20040009897A1 (en) 2004-01-15
BRPI0307724B1 (en) 2019-06-18
WO2003068169A2 (en) 2003-08-21
DK1572074T3 (en) 2012-05-07
JP5237997B2 (en) 2013-07-17
BRPI0307724B8 (en) 2021-05-25
MXPA04007935A (en) 2005-06-08
ES2383172T3 (en) 2012-06-18
JP5156170B2 (en) 2013-03-06
AU2003213091C1 (en) 2009-01-08
ATE540697T1 (en) 2012-01-15
EP1572074A4 (en) 2008-04-30
US8088388B2 (en) 2012-01-03
BR0307724A (en) 2007-04-27

Similar Documents

Publication Publication Date Title
WO2003068169A3 (en) Stabilized synthetic immunogen delivery system
MY125202A (en) Vaccine
EP1546206A4 (en) Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
WO1999041369A3 (en) Genetic vaccine vector engineering
WO1999040936A3 (en) Pneumococcal and meningococcal vaccines formulated with interleukin-12
AU5532601A (en) Targeted vaccine delivery systems
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
GEP20053658B (en) Soluble CTLA4 Mutant Molecules and Uses Thereof
WO2007001677A3 (en) Compositions and methods for immunomodulation in an organism
TR200100936T2 (en) Therapeutic vaccination
WO2003080114A3 (en) Imidazoquinoline adjuvants for vaccines
WO2007067682A3 (en) In vivo cell surface engineering
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
TW200514569A (en) Vaccine composition
WO2005007673A3 (en) Immunogenic peptides
AU2003212170A1 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
GB0207118D0 (en) Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis
ITVA20020024A1 (en) BUILDING PRODUCTS BASED ON HYDROXIALKILGUARO HYDROPHOBIC PURIFIED
AU3436601A (en) Decoding of array sensors with microspheres
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
MXPA02004942A (en) Use of anti idiotypical antibodies as vaccines against cancer.
BR0112258A (en) Poorly Water Soluble Drug Delivery System
WO2004005325A3 (en) Antigen-polymer compositions
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
ITVA20020023A1 (en) PURIFIED HYDROXIALKILGUARO BUILDING PRODUCTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1935/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003213091

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2475102

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003709134

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003567354

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038040212

Country of ref document: CN

Ref document number: PA/a/2004/007935

Country of ref document: MX

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003709134

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0307724

Country of ref document: BR